Rezolute Inc. (RZLT)
4.25
-0.26 (5.76%)
Upcoming Events
Latest Headlines
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026 7:30 AM - Globe NewsWire
Rezolute (RZLT) PT Raised to $14 at Maxim Group
June 3, 2026 8:49 AM - StreetInsider
Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald
June 3, 2026 6:50 AM - StreetInsider
Citizens Upgrades Rezolute (RZLT) to Market Outperform
June 2, 2026 4:53 PM - StreetInsider
Rezolute (RZLT) PT Raised to $6 at Wedbush
June 2, 2026 3:16 PM - StreetInsider
Form 8-K Rezolute, Inc. For: Jun 02
June 2, 2026 7:06 AM - SEC Filing
Rezolute reports interim results from phase 3 tumor hyperinsulinism trial
June 2, 2026 7:00 AM - StreetInsider
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026 7:00 AM - StreetInsider
Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
May 15, 2026 6:36 AM - SEC Filing
Rezolute (RZLT) PT Raised to $10 at Maxim Group
May 14, 2026 8:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
May 13, 2026 7:53 AM - StreetInsider
Rezolute, Inc. (RZLT) Tops Q3 EPS by 2c
May 12, 2026 5:33 PM - StreetInsider
Form 10-Q Rezolute, Inc. For: Mar 31
May 12, 2026 4:21 PM - SEC Filing
Form 8-K Rezolute, Inc. For: May 12
May 12, 2026 4:11 PM - SEC Filing
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Rezolute, Inc. Filed by: Opaleye Management Inc.
May 11, 2026 4:25 PM - SEC Filing
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026 7:00 AM - Globe NewsWire
Form 8-K Rezolute, Inc. For: May 01
May 4, 2026 4:31 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
May 4, 2026 7:29 AM - StreetInsider
Rezolute presents additional Phase 3 sunRIZE data at pediatric meeting
May 1, 2026 12:15 PM - StreetInsider
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026 12:15 PM - Globe NewsWire
Rezolute to present Phase 3 sunRIZE study results at PES meeting
April 21, 2026 7:01 AM - StreetInsider
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 21, 2026 7:01 AM - Globe NewsWire
Form 4 Rezolute, Inc. For: Mar 30 Filed by: Evans Daron
March 31, 2026 5:00 PM - SEC Filing
Form SCHEDULE 13G/A Rezolute, Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 11:08 AM - SEC Filing
Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald After FDA Meeting
March 25, 2026 7:02 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
March 25, 2026 6:58 AM - StreetInsider
Wedbush Upgrades Rezolute (RZLT) to Outperform
March 25, 2026 6:37 AM - StreetInsider
Rezolute (RZLT) Reiterated at Market Perform by Citizens on CHI Program Clarity
March 25, 2026 5:33 AM - StreetInsider
BTIG sees 'incremental positives' in Rezolute (RZLT) regulatory update
March 24, 2026 3:40 PM - StreetInsider
Form 8-K Rezolute, Inc. For: Mar 24
March 24, 2026 7:31 AM - SEC Filing
Rezolute meets with FDA on failed congenital hyperinsulinism study
March 24, 2026 7:00 AM - StreetInsider
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
March 24, 2026 7:00 AM - StreetInsider
Full Article List
